107 related articles for article (PubMed ID: 10680732)
61. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
62. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
63. Prostate cancer incidence and survival in relation to education (United States).
Steenland K; Rodriguez C; Mondul A; Calle EE; Thun M
Cancer Causes Control; 2004 Nov; 15(9):939-45. PubMed ID: 15577296
[TBL] [Abstract][Full Text] [Related]
64. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients.
Zigeuner RE; Lipsky K; Riedler I; Auprich M; Schips L; Salfellner M; Pummer K; Hubmer G
Urology; 2003 Sep; 62(3):451-5. PubMed ID: 12946745
[TBL] [Abstract][Full Text] [Related]
65. Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?
Rohde V; Weidner W; Katalinic A
Urol Int; 2009; 83(2):134-40. PubMed ID: 19752605
[TBL] [Abstract][Full Text] [Related]
66. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria.
Bartsch G; Horninger W; Klocker H; Reissigl A; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P;
Urology; 2001 Sep; 58(3):417-24. PubMed ID: 11549491
[TBL] [Abstract][Full Text] [Related]
67. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
[TBL] [Abstract][Full Text] [Related]
68. Prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
[TBL] [Abstract][Full Text] [Related]
69. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011.
Nordström T; Aly M; Clements MS; Weibull CE; Adolfsson J; Grönberg H
Eur Urol; 2013 Mar; 63(3):419-25. PubMed ID: 23083803
[TBL] [Abstract][Full Text] [Related]
70. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
71. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly.
Hu JC; Williams SB; Carter SC; Eggener SE; Prasad S; Chamie K; Trinh QD; Sun M; Nguyen PL; Lipsitz SR
Urol Oncol; 2015 Feb; 33(2):69.e29-34. PubMed ID: 25017694
[TBL] [Abstract][Full Text] [Related]
72. Recent trends in prostate cancer in Canada.
LeBlanc AG; Demers A; Shaw A
Health Rep; 2019 Apr; 30(4):12-17. PubMed ID: 30994922
[TBL] [Abstract][Full Text] [Related]
73. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.
Feuer EJ; Merrill RM; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1025-32. PubMed ID: 10379965
[TBL] [Abstract][Full Text] [Related]
74. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.
Threlfall TJ; English DR; Rouse IL
Med J Aust; 1998 Jul; 169(1):21-4. PubMed ID: 9695697
[TBL] [Abstract][Full Text] [Related]
75. Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.
Lima CA; da Silva BEB; Hora EC; Lima MS; Brito EAC; Santos MO; da Silva AM; Nunes MAP; Brito HLF; Lima MMM
PLoS One; 2021; 16(3):e0249009. PubMed ID: 33765051
[TBL] [Abstract][Full Text] [Related]
76. Rising prostate cancer rates in South Korea.
Park SK; Sakoda LC; Kang D; Chokkalingam AP; Lee E; Shin HR; Ahn YO; Shin MH; Lee CW; Lee DH; Blair A; Devesa SS; Hsing AW
Prostate; 2006 Sep; 66(12):1285-91. PubMed ID: 16741923
[TBL] [Abstract][Full Text] [Related]
77. Trends in prostate cancer survival in Spain: results from population-based cancer registries.
Marcos-Gragera R; Salmerón D; Izarzugaza I; Ardanaz E; Serdà BC; Larrañaga N; San Román E; Navarro C; Chirlaque MD
Clin Transl Oncol; 2012 Jun; 14(6):458-64. PubMed ID: 22634535
[TBL] [Abstract][Full Text] [Related]
78. Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing.
Kappen S; de Bock GH; Sirri E; Vohmann C; Kieschke J; Winter A
Front Oncol; 2021; 11():681006. PubMed ID: 34123851
[TBL] [Abstract][Full Text] [Related]
79. Incidence, mortality and survival from prostate cancer in Cuba, 1977-1999.
Alvarez YH; Yi ME; Garrote LF; Rodríguez RC
Eur J Cancer Prev; 2004 Oct; 13(5):377-81. PubMed ID: 15452449
[TBL] [Abstract][Full Text] [Related]
80. Geographic disparities in Saskatchewan prostate cancer incidence and its association with physician density: analysis using Bayesian models.
Andkhoie M; Szafron M
BMC Cancer; 2021 Aug; 21(1):948. PubMed ID: 34425772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
